Table 3. Comparison between the diffuse large B-cell lymphoma subtype of iatrogenic immunodeficiency-associated lymphoproliferative disorder and diffuse large B-cell lymphoma.
| DLBCLPTLD DLBCLOIIA (n=13) |
DLBCL, NOS (n=29) |
p | |
|---|---|---|---|
| Immunohistological subtype* | |||
| GCB | 0 | 13 | <0.005 |
| non-GCB | 12 | 16 | |
| EBER | |||
| positive | 8 | 0 | <0.001 |
| negative | 5 | 29 | |
| MYC expression | |||
| positive | 7 | 9 | NS |
| negative | 6 | 20 | |
| MYC translocation** | |||
| positive | 0 | 4 | <0.05 |
| negative | 11 | 5 |
*The immunological subtype of Patient 1 was not determined. **Fluorescent in situ hybridization for MYC translocation was not performed for 2 patients with the diffuse large B-cell lymphoma subtype of other iatrogenic immunodeficiency-associated lymphoproliferative disorder or 20 patients with diffuse large B-cell lymphoma. DLBCLPTLD, diffuse large B-cell lymphoma subtype of post-transplant lymphoproliferative disorder; DLBCLOIIA, diffuse large B-cell lymphoma subtype of other iatrogenic immunodeficiency-associated lymphoproliferative disorder; DLBCL, NOS, diffuse large B-cell lymphoma, not other specified; GCB, germinal center B-cell; EBER, Epstein–Barr virus-encoding small RNA; NS, not significant